View in EDS HTML Full Text PDF Full Text

Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.

Saved in:
Bibliographic Details
Title: Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
Authors: Bodie S; Pulmatrix Inc., Bedford, Massachusetts, USA., Curran AK; Pulmatrix Inc., Bedford, Massachusetts, USA., Gonzalez-Nelson AC; Pulmatrix Inc., Bedford, Massachusetts, USA., Perry JM; Pulmatrix Inc., Bedford, Massachusetts, USA., Manning DC; Veristat, Southborough, Massachusetts, USA., Wasilewski MM; Pulmatrix Inc., Bedford, Massachusetts, USA.
Source: Headache [Headache] 2024 Jun; Vol. 64 (6), pp. 643-651. Date of Electronic Publication: 2024 May 08.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Comparative Study
Journal Info: Publisher: Wiley Country of Publication: United States NLM ID: 2985091R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1526-4610 (Electronic) Linking ISSN: 00178748 NLM ISO Abbreviation: Headache Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38717120
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Bodie+S%22">Bodie S</searchLink>; Pulmatrix Inc., Bedford, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Curran+AK%22">Curran AK</searchLink>; Pulmatrix Inc., Bedford, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Gonzalez-Nelson+AC%22">Gonzalez-Nelson AC</searchLink>; Pulmatrix Inc., Bedford, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Perry+JM%22">Perry JM</searchLink>; Pulmatrix Inc., Bedford, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Manning+DC%22">Manning DC</searchLink>; Veristat, Southborough, Massachusetts, USA.<br /><searchLink fieldCode="AU" term="%22Wasilewski+MM%22">Wasilewski MM</searchLink>; Pulmatrix Inc., Bedford, Massachusetts, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%222985091R%22">Headache</searchLink> [Headache] 2024 Jun; Vol. 64 (6), pp. 643-651. <i>Date of Electronic Publication: </i>2024 May 08.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase I; Comparative Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>2985091R <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1526-4610 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2200178748%22">00178748 </searchLink><i>NLM ISO Abbreviation: </i>Headache <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38717120
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/head.14731
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 643
    Titles:
      – TitleFull: Safety, tolerability, and pharmacokinetics of a single orally inhaled dose of PUR3100, a dry powder formulation of dihydroergotamine versus intravenous dihydroergotamine: A Phase 1 randomized, double-blind study in healthy adults.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Bodie S
      – PersonEntity:
          Name:
            NameFull: Curran AK
      – PersonEntity:
          Name:
            NameFull: Gonzalez-Nelson AC
      – PersonEntity:
          Name:
            NameFull: Perry JM
      – PersonEntity:
          Name:
            NameFull: Manning DC
      – PersonEntity:
          Name:
            NameFull: Wasilewski MM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2024 Jun
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 1526-4610
          Numbering:
            – Type: volume
              Value: 64
            – Type: issue
              Value: 6
          Titles:
            – TitleFull: Headache
              Type: main
ResultId 1